SNCA+nivolumab

Chie Kudo-Saito1, Hiroshi Imazeki2,3, Kengo Nagashima4

  • 1Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp.

Discover oncology
|October 22, 2025
PubMed
概括

增加的α-synuclein (SNCA) 免疫细胞与接受nivolumab治疗的胃癌患者的不良结果相关. 较低的SNCA+细胞水平预测了对抗PD1治疗的持久反应.